Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Carbogen Amcis AG Makes Capital Investments in ADC

Published: Thursday, October 03, 2013
Last Updated: Thursday, October 03, 2013
Bookmark and Share
New ADC capabilities benefit oncology innovators.

Carbogen Amcis AG has announced a series of significant investments aimed at enhancing its antibody drug conjugate (ADC) capabilities to better respond to increasing demand for ADCs in the development of highly targeted cancer treatments.

The investments include a $4 million USD clean room clinical supply facility at the Bubendorf, Switzerland site and a $950,000 USD upgrade of the sterile manufacturing area at the facility in Riom, France.

By adding on to the current High Potency facility, Carbogen Amcis is well positioned to offer its partners seamless development and manufacturing services for ADCs.

“The new targeted cancer treatments, such as Adcetris, Kadcyla and Mylotarg, have fueled a growing demand for ADCs and we made the decision to expand our ADC service offer to support customers in the development of next-generation cancer treatments. We have taken into account customer feedback and market dynamics and are confident that our enhanced infrastructure will enable us to provide our partners in the pharmaceutical industry a needed resource in drug development,” said Mark C. Griffiths, CEO, CARBOGEN AMCIS and the Dishman Group.

The Bubendorf facility now features a new 100-sqm ADC clean room suite dedicated to the development and production of ADC clinical material under current good manufacturing practices (cGMP), and contains grade D and grade C areas to allow aseptic and safe handling of highly potent material at occupational exposure limit values (OELs) below 1 µg/m3 at 8-hour time weighted average (8h-TWA).

A system of pressure cascade and air locks for material and personnel fully segregates both areas of the clean room from the rest of the building and ensures sterile operations within both compartments.

The grade D area of the lab is dedicated to operations such as the preparation of reagents and buffers as well as the sterilization of production equipment by dry oven or autoclave.

The segregated grade C area is exclusively used for the conjugation, the purification, and the packaging of ADC material under cGMP and features (a) an isolator for the preparation of toxin solutions, (b) a barrier system for aseptic filtration, (c) a walk-in fume hood for handling of organic solvents, and (d) a bio-safety cabinet (classified grade C) for antibodies and ADCs.

The upgrades at our Riom, France location include the implementation of a new vaporized hydrogen peroxide (VHP) disinfection system and the installation of two new aseptic filling isolators operating under nitrogen atmosphere and at regulated temperature, which will expand the Grade A (ISO 5) manufacturing capability at OELs below 1 µg/m3 8h-TWA, allowing a maximum batch size up to 5’000 units (2 mL vials).

“In addition to strengthening our ADC capabilities, over the past 12 months, we have built a cross-functional team with expertise in chemistry, biochemistry and biology that is well equipped to support our customers’ cancer drug development programmes,” added Griffiths.

Dr. Scott Miller, head of special projects, a chemist with over 19 years industry experience in the commercialization of oncology drugs, will lead Carbogen Amcis ADC team and will support customers involved in ADC projects.

As major oncology players focus on ADCs as a high-potential opportunity in the development of targeted cancer therapies, Carbogen Amcis offers a valuable outsourcing solution for the complex process of ADC development.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Dengue Virus Exposure May Amplify Zika Infection
Researchers at Imperial College London have found that the previous exposure to the dengue virus may increase the potency of Zika infection.
Itchy Inflammation Of Mosquito Bites Helps Viruses Replicate
The itchy swelling that appears at the site of a mosquito bite isn't just an irritating nuisance - it also makes viral infections spread by the insects far worse, new research has found.
Guided Chemotherapy Missiles
Latching chemotherapy drugs onto proteins that seek out tumors could provide a new way of treating tumors in the brain or with limited blood supply that are hard to reach with traditional chemotherapy.
Revealing T-Cells in Action
Salk scientists show how T-cell receptors reposition during an immune response, revealing more on how the immune system is regulated.
Impact of Antibiotic Treatment on the Infant Gut Microbiome
Study shows that antibiotic treatment reduces stability and diversity of microbial population in the first three years of life.
Viruses Hack Their Host's Genome with CRISPR
A virus that infects major freshwater bacteria appears to use stolen bits of immune system DNA to highjack their hosts’ immune response.
Reclaiming The Immune System's Assault On Tumors
EPFL study shows a way to reclaim corrupted immune cells.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!